A large study of older women suggests metformin may increase the chance of living to age 90.
Scientists are increasingly exploring drugs called gerotherapeutics, treatments that may slow down aging and help people live longer, healthier lives.
One of the most promising candidates is metformin, a widely used medication for type 2 diabetes. Researchers are especially interested in metformin because it appears to influence several key processes related to aging.
In a new multi-institutional study published on May 19, 2025, in the Journal of Gerontology: Medical Sciences, scientists investigated whether metformin could actually help people live longer.
Focusing on postmenopausal women with type 2 diabetes, the study found that those who took metformin were more likely to reach age 90 or older when compared to those using sulfonylureas, another type of diabetes drug.
Key Findings and Implications
The study’s key finding is that the use of metformin is associated with a 30% lower risk of death before age 90 compared to the use of sulfonylurea. However, because metformin was not compared to a placebo, future studies are needed to determine the underlying cause of this association.
Researchers analyzed data from the Women’s Health Initiative (WHI), a large, national cohort study with over 30 years of follow-up, funded by the National Heart, Lung, and Blood Institute at the National Institutes of Health (NIH).
The WHI, which recently had its NIH funding reinstated, has led groundbreaking research in women’s health since the 1990s, generating findings that have shaped clinical practice and public health policies in the United States. Some key facts about WHI:
- 161,808 women (ages 50-79) were enrolled in WHI’s studies in the mid-1990s across 40 clinical centers nationwide.
- Over 42,000 participants (ages 78-108) remain actively involved today.
- WHI provides a unique and comprehensive resource for studying disease risks, early detection, prevention, and aging-related health outcomes.
- It has resulted in over 2,400 scientific publications exploring key aging-related health factors.
As for the current study, led by Associate Professor Aladdin H. Shadyab, Ph.D., M.P.H., and Distinguished Professor Andrea LaCroix, Ph.D., M.P.H., at University of California San Diego Herbert Wertheim School of Public Health and Human Longevity Science and School of Medicine, the authors note that these findings contribute to a growing understanding of metformin’s potential role in promoting human health and longevity.
Reference: “Comparative Effectiveness of Metformin vs Sulfonylureas on Exceptional Longevity in Women with Type 2 Diabetes: Target Trial Emulation” by Aladdin H Shadyab, Mark A Espeland, Andrew O Odegaard, JoAnn E Manson, Bernhard Haring, Karen C Johnson, Zhao Chen, Bowei Zhang and Andrea Z LaCroix, 19 May 2025, The Journals of Gerontology: Series A.
DOI: 10.1093/gerona/glaf095
Never miss a breakthrough: Join the SciTechDaily newsletter.
Follow us on Google and Google News.
4 Comments
What about men under 60 and without diabetes
Regarding metformin. Did the study mention stripping muscle and strength from legs and feet? The ankle to knees area muscle mass is OFTEN depleted weakened, and places stress on hips, back neck.
This article looks like it stretches to find a new purpose for a drug that has satisfied financial needs of a large company. buzz off.
be vegan and plant trees?
the data is misleading in today’s therapeutic landscape. A longevity analysis without considering SGLT2 i and GLP1 a misses the clinical reality